BSE · 524663
Bharat Immunological & Biological Corporation Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹47 Cr with net profit ₹-17 Cr — a -35.98% net margin, versus -11.01% the period before.
Shareholding
As of 2024-03-31
- Promoter59.25%
- Public40.75%
35,313 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.64× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #32 of 50 by market cap · medians across 42 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,988 Cr | 84.86 | 22.12 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,790 Cr | 160.42 | 9.48 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,301 Cr | 112.48 | 3.98 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹24,910 Cr | 100.95 | 19.33 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,293 Cr | 113.41 | 5.38 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,054 Cr | 66.75 | 4.88 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,928 Cr | 51.12 | 4.6 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,809 Cr | 28.26 | 3.91 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹6,025 Cr | 47.67 | 6.45 | 12.36% | 18.59% |
| Bliss GVS Pharma Ltd. | ₹4,853 Cr | 142.11 | 4.06 | 8.95% | 11.15% |
| Bharat Immunological & Biological Corporation Ltd.(this company) | ₹67 Cr | — | — | -22.95% | -236.21% |
AI analysis
AI-generated · google/gemini-2.5-flashBharat Immunological & Biological Corporation Ltd. (BHARATIMMUNOLOGICALSB) has a market capitalization of Rs 73 Cr. The company reported revenue of Rs 47.41 Cr, with a negative profit margin of -236.21%.
Positives
- +The debt-to-equity ratio is 0, indicating no debt.
- +Promoter holding is 59.2543% as of March 31, 2024.
- +No shares are pledged by promoters, with a promoter pledge of 0%.
Negatives
- −Revenue has declined from Rs 87.0129 Cr in Mar 2021 to Rs 47.4122 Cr in Mar 2023.
- −The company has negative net profits of -17.0567 Cr in Mar 2023.
- −The profit margin is significantly negative at -236.21%.
- −Return on Equity (ROE) is negative at -22.95%.
- −The company is under GSM Stage 0 surveillance measures.
Financial Performance
Bharat Immunological & Biological Corporation Ltd. reported revenue of Rs 47.41 Cr for the year ended Mar 2023. This is a decline from Rs 79.49 Cr in Mar 2022 and Rs 87.01 Cr in Mar 2021. The net profit was -17.0567 Cr in Mar 2023, following a net profit of -8.7536 Cr in Mar 2022 and -18.1127 Cr in Mar 2021.
Profitability & Returns
The company's profitability metrics indicate negative returns, with a Return on Equity (ROE) of -22.95% and a Return on Capital Employed (ROCE) of -11.1611%. The profit margin stands at -236.21%. Earnings Per Share (EPS) were -3.95 for Mar 2023, compared to -2.03 in Mar 2022 and 1.1 in Mar 2021.
Balance Sheet
The company has a negative book value of -7.54. The debt-to-equity ratio is 0, indicating no debt. The company does not pay dividends, with a dividend yield of 0%.
Ownership & Pledges
There are no shares pledged by the promoters, with promoter pledge at 0%.
Regulatory & Surveillance
Bharat Immunological & Biological Corporation Ltd. is under GSM (Graded Surveillance Measure) Stage 0. The company faces surveillance measures which include 'GSM'.
Data as of — price: 2026-07-30 · financials: Mar 23 · shareholding: Mar 24. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Bharat Immunological & Biological Corporation Ltd.share price & fundamentals